Cost-Effectiveness Analysis of a Maternal Vaccination Program Against Respiratory Syncytial Virus in Norway.

ABSTRACT:

Background

Respiratory syncytial virus (RSV) is recognized as the primary cause of hospitalizations among children with lower respiratory tract infections in developed countries, placing a significant burden on both patients and healthcare systems. The efficacy, safety, and immunogenicity of maternal vaccination with the novel RSVpreF vaccine have been evaluated in a Phase III clinical trial, showing a decreased risk of severe infection in infants. Our study assesses the cost-effectiveness of the RSVpreF vaccine and seasonal variation of costs in a Norwegian setting.

Methods

A Markov model was used to estimate the clinical outcomes, costs, and quality-adjusted life years of a hypothetical cohort of Norwegian infants born during a single RSV season. A seasonal vaccination pro

SUBMITTER: Værno SG 

PROVIDER: S-EPMC12414795 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature